Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shanghai Regor Enters $1.5 Billion Deal with Lilly for Metabolic Therapies

publication date: Dec 10, 2021

Regor Therapeutics of Shanghai entered into a $1.55 billion research pact with Eli Lilly to discover and develop novel therapies for metabolic disorders. Regor's proprietary CARD (Computer Accelerated Rational Discovery) Platform discoveries innovative candidates for oncology, immunology and metabolic disorders. Lilly will make an upfront $50 million payment for ex-China rights to several Regor metabolic therapies with an option to extend the license. Regor, which will own rights to the candidates in Greater China, is also eligible for $1.5 billion in milestones and royalties. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.